The peroxisome proliferator-activated receptors (PPARs) compose a nuclear receptor subfamily. 1 The three PPAR isoforms, g, a and d, which are encoded by three separate genes, are nutrient sensors that regulate metabolic homeostasis. They are ligand-regulated transcription factors whose main physiological actions are mediated by altering gene expression. PPARs heterodimerize with RXR, then bind to peroxisome proliferator response elements in regulatory domains of genes. Upon being bound by agonists, PPAR conformation is changed such that it binds with high affinity to coactivators that remodel chromatin and communicate with the cellular transcriptional machinery. As a result, transcriptional initiation is induced and the levels of PPAR-responsive transcripts increase. PPARg is highly expressed in adipose tissue. Activation of PPARg induces adipocyte differentiation and lipid accumulation by adipocytes by modulating numerous genes regulating adipogenesis, lipid uptake and lipid metabolism. Notably, PPARg null cells cannot differentiate into adipocytes and the adipose-specific ablation of PPARg results in adipocyte hypocellularity and reduced adiposity. Thiazolidinedione (TZD) insulin-sensitizing agents are PPARg ligands; their antidiabetic efficacy in vivo has been shown to correlate with their receptor agonist potency. The insulin-sensitizing action of PPARg agonists results from their ability to lower circulating free fatty acids by decreasing adipocyte lipolysis, regulate the expression of proteins that modulate insulin action and serve as adipose remodeling agents that direct lipids away from lipolytic visceral fat depots and into subcutaneous fat tissue containing small, insulin-responsive adipocytes.
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PPARg is highly expressed in adipose tissue. Activation of PPARg induces adipocyte differentiation and lipid accumulation by adipocytes by modulating numerous genes regulating adipogenesis, lipid uptake and lipid metabolism. Notably, PPARg null cells cannot differentiate into adipocytes and the adipose-specific ablation of PPARg results in adipocyte hypocellularity and reduced adiposity. Thiazolidinedione (TZD) insulin-sensitizing agents are PPARg ligands; their antidiabetic efficacy in vivo has been shown to correlate with their receptor agonist potency. The insulin-sensitizing action of PPARg agonists results from their ability to lower circulating free fatty acids by decreasing adipocyte lipolysis, regulate the expression of proteins that modulate insulin action and serve as adipose remodeling agents that direct lipids away from lipolytic visceral fat depots and into subcutaneous fat tissue containing small, insulin-responsive adipocytes. 2 PPARg coactivator-1 (PGC-1), a transcriptional coactivator that was first identified as a result of its high affinity for the receptor from which it takes its name, was discussed by Pere Puigserver. Only by interacting with PGC-1 and activating the transcription of mitochondrial UCP-1 can PPARg induce brown adipocyte differentiation. 3 To induce the expression of all the genes required for a complete thermogenic response in brown adipocytes, PGC-1 also serves as a coactivator of other nuclear receptors including PPARa, TR, RAR and ERRa. Additionally, when thermogenesis is required, PGC-1 is upregulated and stabilized by the sympathetic nervous system via activation of b-adrenoreceptor transduction pathways. PGC-1 also plays a critical role in the differentiation and metabolic activity of skeletal muscle, a major site of energy utilization during exercise. 4 The coactivator is sufficient for the induction of mitochondria biogenesis and the generation of type 1 (slow twitch) muscle. Calcium signaling cascades elevate PGC-1 muscle expression by activating transcription factors that have response elements in the coactivator's promoter. Pharmacological activation of PGC-1 in muscle might mitigate obesity. PGC-1 not only induces lipid catabolism but also hepatic gluconeogenesis during the fasted and diabetic states. 5 Glucagon increases PGC-1 expression by cAMP-dependent transduction pathways that synergize with glucocorticoid signaling cascades; the coactivator then interacts with several transcription factors to augment expression of key gluconeogenic enzymes. Inhibition of PGC-1-activated hepatic glucose production may serve as treatment for diabetic hyperglycemia.
Several important interactions between transcription factors and signaling pathways that regulate the complex process of adipogenesis were detailed by Stephen Farmer. C/EBPb and C/EBPd cooperate with glucocorticoids to induce expression of PPARg, which in turn is necessary for C/EBPa expression. 6 These latter two transcription factors are required for terminal adipocyte differentiation. C/EBPb also appears, in concert with a cAMP-dependent pathway, to promote the production of endogenous PPARg agonists by an as yet unknown cellular process. 7 Furthermore, ERK/GSK3-mediated phosphorylation of C/EBPb is necessary for PPARg induction of the expression of C/EBPa and a subset of its target genes, including the important adipocyte-secreted protein adiponectin. b-Catenin, an element in the Wnt signaling pathway, is targeted for proteosomal degradation when phosphorylated by GSK3b. PPARg activation promotes this process, which appears to positively affect PPARg target gene expression and adipogenesis. 8 Several atypical transcription factors that regulate PPARg transcription during the transition between preadipocyte proliferation and adipocyte differentiation, commonly known as the clonal expansion phase, were described by Lluis Fajas. E2F proteins are known to be important regulators of the cell cycle. E2F1 directly activates PPARg expression during clonal expansion of preadipocytes, while E2F4 directly represses transcription of the receptor during terminal adipocyte differentiation.
9 E2F null mice display reduced adiposity, while those with diminished levels of E2F4 are characterized by increased adipogenic potential. The retinoblastoma protein RB has been show to play a role in adipogenesis. Notably, PPARg induces adipocyte differentiation more robustly in the absence of RB because formation of PPARg-RB-HDAC3 complexes represses the nuclear receptor's ability to drive gene expression and adipogenesis. 10 Conversely, dissociation of this receptorcofactor heterotrimer stimulates adipocyte differentiation. In addition to serving as a lipid reservoir, adipose tissue is also an endocrine organ that mediates numerous physiological events via the secretion of adipokines. PPARg regulates the expression of several adipocyte-secreted proteins including adiponectin, the biology of which was described by Philipp Scherer. Adiponectin is a 30 kDa protein containing a short central collagenous region and a C-terminal TNFa-like domain. 11 It circulates as both a hexamer and a high molecular weight (HMW) oligomer. Adiponectin levels are reduced in obese insulin-resistant subjects and type 2 diabetics. Importantly, adiponectin potentiates insulin inhibition of hepatic gluconeogenesis. 12 This insulin-sensitizing activity appears to involve the activation of AMPK. 13 Adiponectin may mediate the hepatic insulin-sensitizing actions of TZDs. Transgenic mice overexpressing the protein display improved glucose tolerance and increased fat accretion, characteristics seen with TZD therapy. Furthermore, treatment of type 2 diabetics with TZDs elevates HMW adiponectin levels in a manner that correlates with their hepatic insulinsensitizing efficacy.
14 Such data support the use of adiponectin as an early biomarker of PPARg agonist antidiabetic activity. In sum, the speakers in these symposium sessions described numerous molecular elements that control nutrient metabolism, energy homeostasis, adipogenesis and insulin signaling. While a central, unifying theme of the presentations was the important role played by the master transcriptional regulator of adipocyte gene expression, PPARg, the research described clearly has evolved well beyond the characterization of that single molecule. It is the hope of this chairperson that such work will continue unabated, not only to embellish our understanding of important areas of biology but also to provide us with additional direction in the search for evermore efficacious therapies for metabolic disease.
